356 related articles for article (PubMed ID: 24252016)
1. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.
Miyagawa I; Nakayamada S; Saito K; Hanami K; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
Mod Rheumatol; 2014 May; 24(3):405-9. PubMed ID: 24252016
[TBL] [Abstract][Full Text] [Related]
2. AA amyloidosis treated with tocilizumab: case series and updated literature review.
Courties A; Grateau G; Philippe P; Flipo RM; Astudillo L; Aubry-Rozier B; Fabreguet I; Fahd W; Fain O; Guggenbuhl P; Hachulla E; Papo T; Richez C; Sibilia J; Morel J; Berenbaum F; Sellam J;
Amyloid; 2015; 22(2):84-92. PubMed ID: 25585627
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases.
Okuda Y; Ohnishi M; Matoba K; Jouyama K; Yamada A; Sawada N; Mokuda S; Murata Y; Takasugi K
Mod Rheumatol; 2014 Jan; 24(1):137-43. PubMed ID: 24261770
[TBL] [Abstract][Full Text] [Related]
7. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: Two case reports.
Fukuda M; Sawa N; Hoshino J; Ohashi K; Motoaki M; Ubara Y
Clin Nephrol; 2021 Jan; 95(1):54-61. PubMed ID: 33155543
[TBL] [Abstract][Full Text] [Related]
9. [Tocilizumab in rheumatoid arthritis].
Rueda Gotor J; Blanco Alonso R
Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
11. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T
Mod Rheumatol; 2008; 18(2):109-18. PubMed ID: 18369528
[TBL] [Abstract][Full Text] [Related]
12. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.
Ugurlu S; Hacioglu A; Adibnia Y; Hamuryudan V; Ozdogan H
Orphanet J Rare Dis; 2017 May; 12(1):105. PubMed ID: 28558744
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
[TBL] [Abstract][Full Text] [Related]
16. Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Kumon Y; Hirata S; Takaoka H
Clin Exp Rheumatol; 2014; 32(4):501-8. PubMed ID: 24959698
[TBL] [Abstract][Full Text] [Related]
17. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Higashi S; Tomoda K; Tsukano M; Baba S
Clin Exp Rheumatol; 2007; 25(4):518-22. PubMed ID: 17888205
[TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.
Lazzerini PE; Acampa M; Capecchi PL; Fineschi I; Selvi E; Moscadelli V; Zimbone S; Gentile D; Galeazzi M; Laghi-Pasini F
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):332-9. PubMed ID: 25186226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
